Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Molecular Therapy Oncolytics
Nancy VillaGrant McFadden

Abstract

Multiple myeloma (MM) is a hematological malignancy of monoclonal plasma cells that remains incurable. Standard treatments for MM include myeloablative regimens and autologous cell transplantation for eligible patients. A major challenge of these treatments is the relapse of the disease due to residual MM in niches that become refractory to treatments. Therefore, novel therapies are needed in order to eliminate minimal residual disease (MRD). Recently, our laboratory reported that virotherapy with oncolytic myxoma virus (MYXV) improved MM-free survival in an allogeneic transplant mouse model. In this study, we demonstrate the capacity of donor autologous murine leukocytes, pre-armed with MYXV, to eliminate MRD in a BALB/c MM model. We report that MYXV-armed bone marrow (BM) carrier leukocytes are therapeutically superior to MYXV-armed peripheral blood mononuclear cells (PBMCs) or free virus. Importantly, when cured survivor mice were re-challenged with fresh myeloma cells, they developed immunity to the same MM that had comprised MRD. In vivo imaging demonstrated that autologous carrier cells armed with MYXV were very efficient at delivery of MYXV into the recipient tumor microenvironment. Finally, we demonstrate that treatment...Continue Reading

References

Oct 29, 2004·The New England Journal of Medicine·Robert A Kyle, S Vincent Rajkumar
Jul 25, 2007·Nature Reviews. Cancer·Teru HideshimaKenneth C Anderson
Aug 31, 2007·Expert Opinion on Biological Therapy·Marianne M Stanford, Grant McFadden
Nov 29, 2008·Leukemia·G D Roodman
Jun 12, 2009·Journal of Virology·Mostafa JarahianFrank Momburg
Mar 10, 2010·Cytokine & Growth Factor Reviews·Masmudur M RahmanGrant McFadden
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Feb 9, 2012·Advances in Virology·Swarna BaisChristopher R Cogle
Apr 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eric BarteeGrant McFadden
Jun 4, 2013·Vaccine·Winnie M ChanGrant McFadden
Mar 7, 2014·Science Translational Medicine·Dmitriy ZamarinJames P Allison
Apr 12, 2014·Blood·Chelsea HopeFotis Asimakopoulos
Jun 23, 2015·Immunotherapy·Douglas B JohnsonMark C Kelley
Sep 2, 2015·Nature Reviews. Drug Discovery·Howard L KaufmanAndrew Zloza
Nov 15, 2016·Nature Medicine·Marta ChesiP Leif Bergsagel
Dec 10, 2016·Molecular Therapy Oncolytics·Eric BarteeXue-Zhong Yu
Feb 2, 2017·Cancer Research·Carlos Alberto FajardoRamon Alemany
Jul 10, 2017·Seminars in Oncology Nursing·Kevin Brigle, Barbara Rogers
Mar 6, 2018·Oncolytic Virotherapy·Eric Bartee
May 11, 2018·Nature Reviews. Immunology·Praveen K BommareddyHoward L Kaufman
May 15, 2018·Frontiers in Immunology·Giulia MarelliYaohe Wang
Jun 16, 2018·Cancers·Christine M CaltonSteffan T Nawrocki
Apr 12, 2019·International Journal of Cancer. Journal International Du Cancer·Iris KoskeDorothee von Laer
Aug 1, 2019·British Journal of Haematology·Susan BalLuciano J Costa
Oct 10, 2019·Expert Review of Anticancer Therapy·Almuth Maria Anni MerzPhilip McCarthy
Oct 19, 2019·The Lancet. Haematology·Francesca Patriarca
Nov 27, 2019·Clinical Lymphoma, Myeloma & Leukemia·Joseph Mikhael
Dec 5, 2019·Therapeutic Advances in Hematology·Cinnie Y Soekojo, Shaji K Kumar
Jan 16, 2020·Journal of Clinical Medicine·Masmudur M Rahman, Grant McFadden

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
X-ray
density gradient purification

Software Mentioned

GraphPad Prism
xPONENT
FlowJo

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.